Impact of the serum bone-specific alkaline phosphatase level at the initiation of hemodialysis therapy for end-stage renal disease on cardiovascular events

Conclusions The serum BAP level at the initiation of HD therapy for ESRD is a useful non-invasive biomarker for predicting CV events.
Source: IJC Metabolic and Endocrine - Category: Endocrinology Source Type: research